Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 11, 2018
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)J Aguilar-Company, M Fernández-Ruiz, R García-Campelo, et al.
Lupus|August 14, 2014
Increased myo-inositol in parietal white and gray matter as a biomarker of poor prognosis in neuropsychiatric lupus: a case reportA Guillen-Del Castillo, J Alonso, F Martínez-Valle, et al.
ESMO Open|October 1, 2025
Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancerS Morganti, R J Kusmick, M E Hughes, et al.
ESMO Open|November 5, 2024
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆A S Raghavendra, D B Zakon, Q Jin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2023
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trialL M Spring, S M Tolaney, G Fell, et al.
ESMO Open|August 29, 2025
Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapyA Strahan, Q Jin, A S Raghavendra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2026
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancerA C Garrido-Castro, S E Kim, T Li, et al.
Pageof 1